The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics around the investing world.
In today's edition, David discusses the recent developments surrounding GlaxoSmithKline's offer for Human Genome Sciences. Shares sit right between their 52-week high and low, but David urges investors not to get greedy. A new poison pill has Glaxo upset, and if the big pharma walks, how will that affect Human Genome Sciences' investors? Watch and find out.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.
David Williamson owns shares of Dendreon. The Motley Fool owns shares of Dendreon and GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.